Computational pharmacology
Drug intelligence, traced back to primary evidence.
Every promising molecule begins as a question: will it bind, will it last, will it be safe. Docking, molecular dynamics, ADMET, pharmacogenomic and pharmacovigilance analysis — written up so your team can hand it to a regulator, an investment committee or a medicinal chemist.
Physician-reviewed before delivery — every page is read end to end by a person who understands the pharmacology, not generated and shipped unread.
- Curated entities
- 17,721Small molecules, biologics and gene therapies
- Cross-domain assets
- 1,114Compounds active in two or more therapeutic domains
- Therapeutic domains
- 8Cardiometabolic through longevity
- Literature grounding
- PubMedLive NCBI retrieval, citations resolvable
What we analyse
Four lines of evidence, one document.
Most vendors sell a database query. The value is the interpretation — what the signal means for your asset, your protocol and your next decision, read and signed off by a person.
Pharmacovigilance & safety
Adverse effects led by the peer-reviewed literature and the label, with spontaneous reports read as a signal against the labelled indication.
- Effects named in the literature, each with citable PMIDs
- Boxed warnings and adverse-reaction sections from the label
- Class-effect comparison against analogues
- Withdrawn-drug precedent analysis
Pharmacogenomics
Metabolic liability mapped to the enzymes that actually clear the compound, including star-allele consequences.
- CYP450 and transporter pathway assignment
- Star-allele phenotype consequences
- Prodrug bioactivation dependency
- Boxed-warning and label precedent
Structure, docking & dynamics
Structure-based work on a named target, with parameters stated so a run can be checked or repeated.
- AutoDock Vina docking with justified box placement
- GNINA convolutional rescoring and decoy controls
- Molecular dynamics and MM/GBSA relative ranking
- Pose interpretation, not just a score
ADMET & liability modelling
Purpose-built models for the off-target risk that would stop a programme, with the uncertainty reported rather than hidden.
- Models trained on curated ChEMBL bioactivity
- Cross-validated, with an applicability-domain check
- Cardiac, barrier, efflux, mutagenicity and hepatotoxicity panels
- Analogue and bioisostere design around a retained pharmacophore
Why this matters now
What computation changes, stage by stage.
Drug discovery has not stopped being slow and expensive. What has changed is where the expensive questions get asked: a liability that used to surface in a preclinical study can now be raised — and often ruled out — before a compound is made.
-
01
Discovery
Target selection
- Structure retrieval from the PDB
- Pathway and mechanism review
- Live literature mining
Asks: is this target plausible, and what is already known against it?
-
02
Hit finding
Virtual screening
- Fingerprint similarity across curated chemical space
- Docking into a justified pocket
- Deep-learned pose rescoring
Replaces: screening a plate to find out a series was never going to fit.
-
03
Lead optimisation
Design and liability
- Analogue and bioisostere enumeration
- Machine-learned off-target models
- Molecular dynamics and binding-energy ranking
Asks: which of a thousand analogues is worth a chemist’s week?
-
04
Preclinical
ADMET and genotype
- Cardiac, barrier, efflux and hepatic panels
- CYP and transporter pathway assignment
- Star-allele consequence mapping
Surfaces: the metabolic surprise that would otherwise appear in Phase 1.
-
05
Clinical and beyond
Stratify and monitor
- Genotype-guided inclusion criteria
- Reported adverse-event signal mining
- Class and withdrawn-drug precedent
Asks: who should be in this trial, and what has the class already done to people?
Earlier, not instead
Computation moves a question forward in time. A patch-clamp assay still settles cardiac risk — but it is cheap once you know which two compounds to run it on.
Negative results, early
The most valuable output is often a ruled-out hypothesis. A model that cannot separate your analogues is told to say so rather than produce a ranking.
Traceable, not oracular
Every figure resolves to a PDB code, a PMID, a database version or a stated parameter. Nothing rests on a number whose origin cannot be shown.
How it works
Free where a machine can answer.
The platform and the first look cost nothing, and they are not a trial. What is charged for is the part a machine cannot do.
Free, for everyone
Open to academics, scientists, industry teams and investors. No account, no card, no expiry.
- The platform — about 17,721 molecules, searchable, with six ways to search
- A one-page technical snapshot on any compound or ClinicalTrials.gov number
- A short technical sanity-check for investors, on one pipeline asset
Where human work starts
Analysis that requires a trained reading: interpretation, design, and a written argument you can act on.
- Pharmacogenomic panel evaluation and protocol-level recommendations
- Technical due diligence memos ahead of an investment decision
- Docking, dynamics, ADMET and analogue design on a named target
Scope, depth and turnaround differ too much between engagements for a list price to mean anything. Describe the compound and the decision it has to inform, and you will get a personalised offer.
No cost, no obligation
Send a compound. Get a technical snapshot back.
No account, no card. Tell us the compound and the question; the first thing back is a one-page technical snapshot at no charge.